Latest On Itamar Medical Ltd (ITMR):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-11-18 08:23 EST | News | Itamar Medical EPS beats by $0.23, beats on revenue | N/A |  |
| 2021-09-22 18:32 EST | News | Itamar Medical stock surge on being taken over by Zoll Medical for ~$538M | N/A | |
| 2021-08-10 18:41 EST | News | Itamar Medical EPS misses by $0.02, beats on revenue | N/A | |
| 2021-08-10 18:41 EST | News | Itamar Medical Ltd.'s (ITMR) CEO Gilad Glick on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-22 16:48 EST | News | Teleflex and Itamar sell off “too draconian”: Piper Sandler | N/A | |
| 2021-03-09 10:11 EST | Analyst Rating | The Analyst Target Price has increased from $29.66 to $30.51. | Buy | |
| 2021-03-03 22:38 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-03 10:19 EST | Analyst Rating | The Analyst Target Price has increased from $28.66 to $29.66. | Buy | |
| 2021-03-03 01:19 EST | News | Itamar Medical Ltd. (ITMR) CEO Gilad Glick on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-02 06:41 EST | News | Itamar Medical EPS beats by $0.12, beats on revenue | N/A | |
| 2021-02-05 20:56 EST | News | Itamar Medical prices ADSs offering | N/A | |
| 2021-02-05 02:59 EST | News | Itamar Medical launches ADS offering | N/A | |
| 2021-01-20 10:12 EST | Analyst Rating | The Analyst Target Price has increased from $28.34 to $28.66. | Buy | |
| 2021-01-12 18:41 EST | News | Itamar Medical acquires Spry Health | N/A | |
| 2021-01-08 12:48 EST | News | Itamar Medical sees Q4 revenue above consensus | N/A | |
| 2020-12-04 06:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-19 23:28 EST | Earnings Estimate | An EPS average of -$0.17 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2020-11-19 23:28 EST | Analyst Rating | The Analyst Target Price has increased from $28.06 to $28.34. | Buy | |
| 2020-11-19 15:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-19 08:20 EST | News | Itamar Medical Ltd. 2020 Q3 - Results - Earnings Call Presentation | N/A | |
| 2020-11-18 15:33 EST | Analyst Rating | The Analyst Target Price has increased from $27.84 to $28.06. | Buy | |
| 2020-11-18 04:55 EST | News | Itamar Medical EPS beats by $0.14, beats on revenue | N/A | |
| 2020-11-18 04:54 EST | News | Itamar Medical Ltd. (ITMR) CEO Gilad Glick on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-10-15 07:48 EST | News | Itamar Medical sees Q3 as high as $11M, above consensus | N/A | |
| 2020-10-15 07:09 EST | Analyst Rating | The Analyst Target Price has increased from $26.94 to $27.84. | Buy | |
| 2020-10-14 07:37 EST | Analyst Rating | The Analyst Target Price has increased from $26.76 to $26.94. | Buy | |
| 2020-10-08 20:59 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-04 15:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-02 10:24 EST | News | Itamar Medical’s WatchPAT300 OK'd in Japan | N/A | |
| 2020-09-26 16:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 09:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-26 08:16 EST | Analyst Rating | The Analyst Target Price has increased from $25.99 to $26.76. | Buy | |
| 2020-08-18 03:30 EST | Analyst Rating | The Analyst Target Price has increased from $24.99 to $25.99. | Buy | |
| 2020-08-14 12:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-13 15:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-12 07:50 EST | Analyst Rating | The Analyst Target Price has increased from $23.74 to $24.99. | Neutral | |
| 2020-08-12 07:18 EST | News | Itamar Medical EPS beats by $0.16, beats on revenue | N/A | |
| 2020-08-12 07:18 EST | News | Itamar Medical Ltd. (ITMR) CEO Gilad Glick on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-08-06 16:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 12:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 15:25 EST | Analyst Rating | The Analyst Target Price has increased from $23.31 to $23.74. | Neutral | |
| 2020-07-28 16:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 21:08 EST | Financials | Company financials have been released. | Neutral | |
About Itamar Medical Ltd (ITMR):
Itamar Medical Ltd. engages in the research, development, marketing, sale, and leasing of non-invasive medical devices for the cardiology market. The company offers medical devices based on Peripheral Arterial Tone (PAT) signal, which measures changes in the patient's peripheral arterial pulse volumes and various parameters of arterial activities. It provides WatchPAT device, which enables home sleep tests for various sleeping disorders, including obstructive sleep apnea; and Endo PAT device that diagnoses endothelial dysfunction. The company operates in the United States, Canada, Europe, Israel, Japan, the Asia Pacific, and other countries. Itamar Medical Ltd. has a collaboration agreement with SoClean Inc. to offer WatchPAT ONE home sleep apnea test and digital health services through direct-to-consumer channels. The company was formerly known as Itamar Medical (CM) 1997 Ltd. and changed its name to Itamar Medical Ltd. in July 2000. Itamar Medical Ltd. was founded in 1997 and is headquartered in Caesarea, Israel.
General
- Name Itamar Medical Ltd
- Symbol ITMR
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryMedical Devices
- Fiscal Year EndDecember
- IPO Date2019-03-07
- Gic SectorHealth Care
- Gic GroupHealth Care Equipment & Services
- Gic IndustryHealth Care Equipment & Supplies
- Web URLhttp://www.itamar-medical.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 8.01
- Price/Book (Most Recent Quarter) 9.03
- Enterprise Value Revenue 8.5
View More
Financials
- Most Recent Quarter 2020-12-31
- Next Quarter EPS Estimate -$0.22
- Profit Margin -27%
- Operating Margin -25%
- Return on Assets -13%
- Return on Equity -37%
- Revenue 41.03 million
- Earnings Per Share -$0.69
- Revenue Per Share $2.97
- Gross Profit 28.71 million
- Quarterly Earnings Growth 30.8%
View More
Highlights
- Market Capitalization 364.49 million
- EBITDA -3547000
- Analyst Target Price $30.51
- Book Value Per Share $3.06
View More
Share Statistics
- Shares Outstanding 16.38 million
- Shares Float 10.04 million
- % Held by Insiders 441%
- % Held by Institutions 41.47%
- Shares Short 283674
- Shares Short Prior Month 303256
- Short Ratio 5.63
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 0.63
- 52 Week High $26.83
- 52 Week Low $8.19
- 50 Day Moving Average 24.39
- 200 Day Moving Average 21.79
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Itamar Medical Ltd (ITMR) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Itamar Medical Ltd (ITMR) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-02 | $12.77 million | -$0.21 | -$0.13 | -63.68% |
| 2020-09-30 | 2020-11-17 | $11 million | -$0.20 | -$0.16 | -29.03% |
| 2020-06-30 | 2020-08-11 | $8.89 million | -$0.23 | -$0.19 | -22.15% |
| 2020-03-31 | 2020-05-27 | $8.38 million | -$0.15 | -$0.14 | -5.63% |
| 2019-12-31 | 2020-03-03 | $9.77 million | -$0.09 | -$0.05 | -68.86% |
| 2019-09-30 | 2019-11-26 | $8.08 million | $-0.00 | -$0.10 | 97% |
| 2019-06-30 | 2019-08-14 | $7.35 million | -$0.18 | -$0.13 | -38.46% |
| 2019-03-31 | 2019-04-10 | $6.06 million | -$0.12 |
Itamar Medical Ltd (ITMR) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 1.94 million | 1.39 million | 1.38 million | 1.3 million | 1.36 million |
| Income Before Tax | -2.96 million | -2.66 million | -3.23 million | -1.96 million | -1.1 million |
| Selling General Administrative | 9.56 million | 8.66 million | 7.86 million | 6.98 million | 7.17 million |
| Gross Profit | 8.84 million | 7.53 million | 6.02 million | 6.33 million | 7.65 million |
| Ebit | -1.87 million | -1.92 million | -2.59 million | -1.31 million | -1.32 million |
| Operating Income | -2.66 million | -2.51 million | -3.22 million | -1.96 million | -877000 |
| Income Tax Expense | N/A | 95000 | 10000 | N/A | -98000 |
| Total Revenue | 12.77 million | 11 million | 8.89 million | 8.38 million | 9.77 million |
| Cost of Revenue | 3.93 million | 3.47 million | 2.87 million | 2.05 million | 2.12 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -158000 |
| Net Income From Continuing Operations | -2.94 million | -2.76 million | -3.24 million | -2 million | -999000 |
| Net Income Applicable to Common Shares | N/A | -2.76 million | -3.24 million | N/A | -999000 |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -9.4 million | -8.03 million | -231000 | 8.86 million | -212000 |
| Change to Liabilities | 782000 | 151000 | N/A | -187000 | 199000 |
| Total Cash Flow from Investing Activities | -9.4 million | -8.03 million | N/A | 8.86 million | -212000 |
| Net Borrowings | -220000 | -220000 | N/A | -204000 | -144000 |
| Total Cash Flow from Financial Activities | -207000 | -1.02 million | 36.84 million | -116000 | -146000 |
| Change to Operating Activities | 979000 | 336000 | N/A | 1.14 million | 192000 |
| Change in Cash | -12.51 million | -12.79 million | 35.2 million | 6.67 million | -633000 |
| Total Cash from Operating Activities | -2.91 million | -3.74 million | -1.41 million | -2.08 million | -275000 |
| Depreciation | 456000 | 479000 | 410000 | 387000 | 385000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | -68000 | -68000 |
| Change to Inventory | -1.96 million | -1.05 million | -761000 | -426000 | -633000 |
| Change to Account Receivables | -867000 | -728000 | 1.18 million | -2.43 million | 388000 |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | -787000 | -583000 |
| Change to Net Income | 460000 | 315000 | N/A | 438000 | 341000 |
| Capital Expenditures | 895000 | 478000 | 231000 | 141000 | 144000 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 21.07 million | 18.03 million | 16.54 million | 16.02 million | 16.54 million |
| Total Stockholder Equity | 43.07 million | 46.04 million | 48.38 million | 51.64 million | 16.66 million |
| Other Current Liabilities | N/A | 3.9 million | N/A | N/A | 3.73 million |
| Total Assets | 64.14 million | 64.07 million | 64.92 million | 67.66 million | 33.21 million |
| Common Stock | N/A | 1.14 million | 1.13 million | N/A | 878000 |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -119.07 million | -116.56 million | -114.16 million | -111.22 million | -109.65 million |
| Other Liabilities | N/A | 1.48 million | 1.47 million | N/A | 1.52 million |
| Other Assets | N/A | 912000 | 782000 | N/A | 909000 |
| Cash | 9.67 million | 25.15 million | 37.67 million | 50.44 million | 15.12 million |
| Total Current Liabilities | 17.99 million | 15.41 million | 13.82 million | 13.12 million | 13.32 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | N/A | 4.37 million | 3.89 million | N/A | 3.91 million |
| Total Current Assets | 57.44 million | 57.94 million | 59.57 million | 62.64 million | 28.27 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | N/A | 45.18 million | 47.7 million | N/A | 16.55 million |
| Short Term Investments | 30 million | 16 million | 7.5 million | N/A | N/A |
| Long Term Debt | 154000 | N/A | N/A | N/A | N/A |
| Inventory | 7.16 million | 6.48 million | 4.73 million | 3.91 million | 3.36 million |
| Accounts Payable | 4.42 million | 3.39 million | 2.65 million | 2.97 million | 2.03 million |
Itamar Medical Ltd (ITMR) Chart:
Itamar Medical Ltd (ITMR) News:
Below you will find a list of latest news for Itamar Medical Ltd (ITMR) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Itamar Medical Ltd (ITMR) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Itamar Medical Ltd (ITMR) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920067933/0001104659-20-067933-index.htm |
| 2020-01-28 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1613170/000000000020000723/0000000000-20-000723-index.htm |
| 2019-10-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465919055713/0001104659-19-055713-index.htm |
| 2019-10-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465919058065/0001104659-19-058065-index.htm |
| 2019-11-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465919059228/0001104659-19-059228-index.htm |
| 2019-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465919063586/0001104659-19-063586-index.htm |
| 2019-11-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465919067193/0001104659-19-067193-index.htm |
| 2019-12-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465919069205/0001104659-19-069205-index.htm |
| 2019-12-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465919069762/0001104659-19-069762-index.htm |
| 2019-12-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465919071593/0001104659-19-071593-index.htm |
| 2020-01-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920003168/0001104659-20-003168-index.htm |
| 2020-01-14 | DRS | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1613170/000110465920003984/0001104659-20-003984-index.htm |
| 2020-01-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920004120/0001104659-20-004120-index.htm |
| 2020-01-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920004881/0001104659-20-004881-index.htm |
| 2020-01-28 | F-1 | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1613170/000110465920007718/0001104659-20-007718-index.htm |
| 2020-01-28 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1613170/000110465920007727/0001104659-20-007727-index.htm |
| 2020-01-28 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1613170/000110465920007728/0001104659-20-007728-index.htm |
| 2020-01-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920007734/0001104659-20-007734-index.htm |
| 2020-01-29 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1613170/000110465920008115/0001104659-20-008115-index.htm |
| 2020-01-30 | F-1MEF | Registration statement to add securities to prior Form F-1 registration [Rule 462(b)] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920008884/0001104659-20-008884-index.htm |
| 2020-01-31 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920009321/0001104659-20-009321-index.htm |
| 2020-01-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920009328/0001104659-20-009328-index.htm |
| 2020-02-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613170/000110465920016172/0001104659-20-016172-index.htm |
| 2020-02-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920016302/0001104659-20-016302-index.htm |
| 2020-03-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920028173/0001104659-20-028173-index.htm |
| 2020-03-04 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1613170/000110465920029134/0001104659-20-029134-index.htm |
| 2020-03-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920032141/0001104659-20-032141-index.htm |
| 2020-03-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920035665/0001104659-20-035665-index.htm |
| 2020-03-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920036632/0001104659-20-036632-index.htm |
| 2020-04-03 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920043200/0001104659-20-043200-index.htm |
| 2020-04-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920045728/0001104659-20-045728-index.htm |
| 2020-04-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920048478/0001104659-20-048478-index.htm |
| 2020-05-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920055804/0001104659-20-055804-index.htm |
| 2020-05-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920066026/0001104659-20-066026-index.htm |
| 2020-06-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920067933/0001104659-20-067933-index.htm |
| 2020-07-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920083768/0001104659-20-083768-index.htm |
| 2020-07-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920086822/0001104659-20-086822-index.htm |
| 2020-08-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920092941/0001104659-20-092941-index.htm |
| 2020-08-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920094429/0001104659-20-094429-index.htm |
| 2020-08-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920097019/0001104659-20-097019-index.htm |
| 2020-08-20 | 6-K/A | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920097057/0001104659-20-097057-index.htm |
| 2020-10-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920114049/0001104659-20-114049-index.htm |
| 2020-10-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920115760/0001104659-20-115760-index.htm |
| 2020-11-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000110465920120694/0001104659-20-120694-index.htm |
| 2019-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000114420419039710/0001144204-19-039710-index.htm |
| 2019-08-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1613170/000114420419041020/0001144204-19-041020-index.htm |
| 2019-09-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613170/000117891319002335/0001178913-19-002335-index.htm |
| 2020-02-06 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613170/000117891320000286/0001178913-20-000286-index.htm |
| 2020-02-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613170/000117891320000391/0001178913-20-000391-index.htm |
| 2020-02-18 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613170/000117891320000554/0001178913-20-000554-index.htm |
| 2019-08-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613170/000119312519216958/0001193125-19-216958-index.htm |
| 2020-02-10 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1613170/000121390020003043/0001213900-20-003043-index.htm |
| 2020-01-30 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1613170/999999999520000200/9999999995-20-000200-index.htm |